H Abdollahi, I Shiri, J J Bevelacqua, A Jafarzadeh, A Rahmim, H Zaidi, S A R Mortazavi, S M J Mortazavi
PhD, Department of Radiologic Sciences and Medical Physics, Faculty of Allied Medicine, Kerman University of Medical Science, Kerman, Iran.
PhD, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211 Geneva 4, Switzerland.
J Biomed Phys Eng. 2020 Aug 1;10(4):387-394. doi: 10.31661/jbpe.v0i0.2006-1125. eCollection 2020 Aug.
Physicians and scientists around the world are aggressively attempting to develop effective treatment strategies. The treatment goal is to reduce the fatality rate in 15% to 20% of individuals infected with SARS-CoV-2 who develop severe inflammatory conditions that can lead to pneumonia, and acute respiratory distress syndrome. These conditions are major causes of death in these patients. Convalescent plasma (CP) collected from patients recovered from the novel corona virus disease (COVID-19) has been considered as an effective treatment method for COVID-19. Moreover, low-dose radiation therapy (LDRT) for COVID-19 pneumonia was historically used to treat pneumonia during the first half of the 20 century. The concept of LDRT for COVID-19 pneumonia was first introduced in March 2020. Later scientists from Canada, Spain, United States, Germany and France also confirmed the potential efficacy of LDRT for treatment of COVID-19 pneumonia. The rationale behind introducing LDRT as an effective treatment method for pneumonia in COVID-19 patients is not only due to its anti-inflammatory effect, but also in optimization of the activity of the immune system. Moreover, LDRT, unlike other treatment methods such as antiviral drugs, does not have the key disadvantage of exerting a significant selective pressure on the SARS-CoV-2 virus and hence does not lead to evolution of the virus through mutations. Given these considerations, we believe that a hybrid treatment including both CP and LDRT can trigger synergistic responses that will help healthcare providers in mitigating today's COVID-19 pandemic.
世界各地的医生和科学家都在积极尝试制定有效的治疗策略。治疗目标是将感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）并发展为可导致肺炎和急性呼吸窘迫综合征的严重炎症的患者的死亡率降低15%至20%。这些病症是这些患者死亡的主要原因。从新型冠状病毒病（COVID-19）康复患者中采集的康复期血浆（CP）被认为是治疗COVID-19的有效方法。此外，用于治疗COVID-19肺炎的低剂量放射治疗（LDRT）在20世纪上半叶曾被用于治疗肺炎。LDRT用于COVID-19肺炎的概念于2020年3月首次提出。后来，来自加拿大、西班牙、美国、德国和法国的科学家也证实了LDRT治疗COVID-19肺炎的潜在疗效。将LDRT作为COVID-19患者肺炎的有效治疗方法背后的基本原理不仅在于其抗炎作用，还在于优化免疫系统的活性。此外，与抗病毒药物等其他治疗方法不同，LDRT不会对SARS-CoV-2病毒施加显著的选择压力，因此不会导致病毒通过突变进化。考虑到这些因素，我们认为包括CP和LDRT的联合治疗可以引发协同反应，这将有助于医护人员缓解当前的COVID-19大流行。
